- Home
- APRE vs EDSA Comparison
APRE vs EDSA Comparison
Compare APRE & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | EDSA |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 7.5M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | APRE | EDSA |
|---|---|---|
| Price | $0.84 | $6.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.50 | ★ $13.00 |
| AVG Volume (30 Days) | 252.0K | ★ 7.1M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.72 |
| 52 Week High | $2.76 | $7.43 |
Technical Indicators
Market Signals| Indicator | APRE | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 80.64 |
| Support Level | $0.55 | $1.71 |
| Resistance Level | $1.02 | N/A |
| Average True Range (ATR) | 0.09 | 1.03 |
| MACD | 0.01 | 0.61 |
| Stochastic Oscillator | 59.42 | 74.06 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.